OLD Second National Bank of Aurora Has $2.68 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

OLD Second National Bank of Aurora decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,051 shares of the biopharmaceutical company’s stock after selling 14 shares during the period. OLD Second National Bank of Aurora’s holdings in Regeneron Pharmaceuticals were worth $2,680,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Ronald Blue Trust Inc. boosted its position in shares of Regeneron Pharmaceuticals by 18.8% during the third quarter. Ronald Blue Trust Inc. now owns 76 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 12 shares in the last quarter. Drive Wealth Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 4.0% during the fourth quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 12 shares in the last quarter. Cassia Capital Partners LLC boosted its position in shares of Regeneron Pharmaceuticals by 2.3% during the third quarter. Cassia Capital Partners LLC now owns 589 shares of the biopharmaceutical company’s stock worth $485,000 after purchasing an additional 13 shares in the last quarter. Sutton Wealth Advisors Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 38.2% during the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 13 shares during the period. Finally, Clearview Wealth Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 1.5% during the fourth quarter. Clearview Wealth Advisors LLC now owns 855 shares of the biopharmaceutical company’s stock worth $751,000 after acquiring an additional 13 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total value of $95,422.00. Following the completion of the sale, the director now owns 18,382 shares of the company’s stock, valued at approximately $17,540,472.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the sale, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $954.22, for a total transaction of $95,422.00. Following the completion of the sale, the director now directly owns 18,382 shares in the company, valued at $17,540,472.04. The disclosure for this sale can be found here. In the last 90 days, insiders sold 13,729 shares of company stock valued at $13,124,641. Corporate insiders own 8.83% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Morgan Stanley lifted their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. Bank of America lifted their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. StockNews.com upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 12th. BMO Capital Markets lifted their price target on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. Finally, UBS Group lifted their price objective on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $976.41.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $2.62 during trading hours on Thursday, reaching $898.57. 102,449 shares of the company were exchanged, compared to its average volume of 490,089. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $98.63 billion, a P/E ratio of 25.93, a P/E/G ratio of 2.58 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $998.33. The business’s 50 day simple moving average is $955.19 and its 200-day simple moving average is $890.52.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. The business had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. Regeneron Pharmaceuticals’s revenue for the quarter was up .6% on a year-over-year basis. During the same period in the previous year, the business posted $10.96 earnings per share. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.58 earnings per share for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.